Shares in Celgene (NSDQ:CELG) fell yesterday, even though the biopharmaceutical company beat earnings expectations on Wall Street with its 4th quarter results.
The Summit, N.J.-based company posted profits of $1.29 million, or $1.61 per share, on sales of $2.9 million for the 3 months ended Dec. 31, for bottom-line growth of 34% on sales growth of 17% compared with the same period last year.
Get the full story at our sister site, Drug Delivery Business News.